Loading...
•
Dec 31, 2020
Guardant Health Q4 2020 Earnings Report
Guardant Health's revenue increased driven by precision oncology and development services.
Key Takeaways
Guardant Health reported a 25% increase in revenue for the fourth quarter of 2020, reaching $78.3 million. The growth was primarily driven by a 47% increase in clinical testing revenue and a 148% increase in development services revenue. However, the company experienced a net loss of $93.7 million, or $0.94 per share, compared to a net loss of $25.2 million, or $0.27 per share, in the same period of the previous year.
Revenue reached $78.3 million, a 25% increase compared to Q4 2019.
Clinical testing revenue grew by 47% year-over-year.
Development services revenue increased by 148% year-over-year.
Net loss was $93.7 million, or $0.94 per share.
Revenue by Segment
Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.
Positive Outlook
- Full year 2021 revenue expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% over full year 2020 is anticipated.
- Clinical volumes for 2021 are expected to be greater than 90,000 tests.
- Clinical test volume is expected to grow at least 42% over 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...